Adalimumab in the treatment of rheumatoid arthritis

Bibliography

• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36:182-8
   PubMed Web of Science ®Google Scholar
• Drosos AA, Alamanos I, Voulgari PV, et al. Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J Rheumatol 1997;24:2129-33
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 2006;6(12):1349-60
   PubMed Web of Science ®Google Scholar
• Giles JT. Management of rheumatoid arthritis: synovitis. In: Hochberg MC, editor, Rheumatology. 4th edition. Mosby, Elsevier, Philadelphia, PA, USA; 2008. p.887-90
   Google Scholar
• Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353(9149):259-66
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39(6):655-65
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344(8930):1105-10
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al.; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72(4):482-92
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013, doi:10.1136/annrheumdis-2013-204573
   Google Scholar
• Papagoras C, Voulgari PV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010;9:574-82
   PubMed Web of Science ®Google Scholar
• Markatseli TE, Alamanos Y, Saougou I, et al. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol 2012;30(1):31-8
   PubMed Web of Science ®Google Scholar
• Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Long-term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol 2013;5:43-9
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
   PubMed Web of Science ®Google Scholar
• Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
   PubMed Web of Science ®Google Scholar
• Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004;18(2):121-39
   PubMed Web of Science ®Google Scholar
• Santora LC, Krull IS, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem 1999;275(1):98-108
   PubMed Web of Science ®Google Scholar
• Adalimumab EMA. Summary of product characteristics. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/487292/2012
   Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• ABBOTT. Humira (package insert). Abbott, Abbott Park, IL, USA; 2006
   Google Scholar
• Awni VM, Cascella P, Oleka N, et al. Steady-state pharmacokinetics of adalimumab (HumiraTM) following 40 mg subcutaneous injection every other week in rheumatoid arthritis patients with and without methotrexate background therapy [abstract]. Arthritis Rheum 2003;48(Suppl):S141
   Google Scholar
• den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29(11):2288-98
   PubMed Web of Science ®Google Scholar
• Papagoras C, Voulgari PV, Drosos AA. Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol Res Rev 2009;1:51-68
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
   PubMed Web of Science ®Google Scholar
• Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents–a guide for GPs. Aust Fam Physician 2007;36(12):1035-8
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30(12):2563-71
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63(5):508-16
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48(1):35-45
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50(5):1400-11
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66(6):732-9
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rudwaleit M, van den Bosch F, et al. Adalimumab (Humira®) therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriatic arthritis (PSA) patients with a history of anti-TNF therapy. Ann Rheum Dis 2008;67(Suppl II):177
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65(6):753-9
   PubMed Web of Science ®Google Scholar
• Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34(5):353-8
   PubMed Web of Science ®Google Scholar
• Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006;65(2):257-60
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72(11):1777-85
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70(3):404-13
   PubMed Web of Science ®Google Scholar
• Keystone EC, Shirinsky VS, Simon LS, et al.; CH-1504 Study Group. Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. J Rheumatol 2011;38(9):1875-83
   PubMed Web of Science ®Google Scholar
• Strand V, Rentz AM, Cifaldi MA, et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012;39:63-72
   PubMed Web of Science ®Google Scholar
• Laas K, Peltomaa R, Puolakka K, et al. Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice. Clin Exp Rheumatol 2009;27:315-20
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Kivitz A, van Vollenhoven RF, et al. No differences in patient-reported outcomes by methotrexate dose among early rheumatoid arthritis patients treated concomitantly with adalimumab: results from the CONCERTO trial. Arthritis Rheum 2013;65(Suppl):S574-5
   Google Scholar
• Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy, pharmacokinetics, and safety of different doses of methotrexate in combination with adalimumab: results from the CONCERTO trial. Arthritis Rheum 2013;65(Suppl):S183-4
   Google Scholar
• Burmester GR, Kivitz AJ, van Vollenhoven RF, et al. Methotrexate dose has minimal effects on methotrexate-related toxicity in patients with early rheumatoid arthritis treated in combination with adalimumab – results of CONCERTO trial. Arthritis Rheum 2013;65(Suppl):S1148-9
   PubMedGoogle Scholar
• Chada A, Goss SL, Klein CE, et al. Adalimumab in combination with high and low dose-methotrexate in rheumatoid arthritis patients with inadequate response to methotrexate: pharmacokinetic results from the MUSICA study. Arthritis Rheum 2013;65(Suppl):S623-4
   Google Scholar
• Kaeley GS, Evangelisto AM, Nishio MJ, et al. Impact of methotrexate dose reduction upon initiation of adalimumab on clinical and ultrasonographic parameters in patients with moderate to severe arthritis. Arthritis Rheum 2013;65(Suppl):S1147
   Google Scholar
• van der Heijde D, Landewe R, Sharp JT, et al. Initial combination therapy with adalimumab and methotrexate leads to better long-term inhibition of radiographic progression in early RA: 5-year results of the PREMIER Trial [abstract 995]. American College of Rheumatology, Annual Meeting; 24 – 29 October 2008; San Francisco, USA
   Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Inhibition of radiographic progression in patients with long-standing rheumatoid arthritis treated with adalimumab plus methotrexate for 5 years. Ann Rheum Dis 2007;66(Suppl II):176
   Google Scholar
• Smolen JS, van der Heijde DM, Keystone EC, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis 2013;72(7):1156-62
   PubMed Web of Science ®Google Scholar
• Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72(6):844-50
   PubMed Web of Science ®Google Scholar
• van Eijk IC, Nielen MM, van der Horst-Bruinsma I, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford) 2012;51(4):686-94
   PubMed Web of Science ®Google Scholar
• Keystone EC, van der Heijde D, Kavanaugh A, et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013;40(9):1487-97
   PubMed Web of Science ®Google Scholar
• Iagnocco A, Filippucci E, Perella C, et al. Clinical and ultrasonographic monitoring of response to adalimumab treatment in rheumatoid arthritis. J Rheumatol 2008;35(1):35-40
   PubMed Web of Science ®Google Scholar
• Zikou AK, Argyropoulou MI, Voulgari PV, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J Rheumatol 2006;33(2):219-23
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10(3):289-300
   PubMed Web of Science ®Google Scholar
• Exarchou SA, Voulgari PV, Markatseli TE, et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009;38:328-31
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:567-70
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Kaltsonoudis E, Papagoras C, Drosos AA. Adalimumab in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012;12(12):1679-86
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M.; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25(1):56-64
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Alonso-Ruiz A, Pijoan J, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety BMC Musculoskeletal Disorders. 2008;9:52
   Google Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68(7):1136-45
   PubMed Web of Science ®Google Scholar
• Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of longterm data. J Rheumatol 2011;38(8):1552-62
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306(21):2331-9
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011;70(8):1401-6
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al.; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50(1):124-31
   PubMed Web of Science ®Google Scholar
• Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8(3):266-73
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38(9):1261-5
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39(8):1254-5
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Valverde VR, et al.; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48(8):2122-7
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al.; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69(3):522-8
   PubMed Web of Science ®Google Scholar
• Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al.; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52(6):1766-72
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57(5):756-61
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Muntner PM, et al. Does the association between anti-TNF biologics and serious infections in rheumatoid arthritis patients vary by comorbidity burden? [abstract]. Arthritis Rheum 2011;63(Suppl 10):462
   Google Scholar
• Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66(10):1339-44
   PubMed Web of Science ®Google Scholar
• Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10(2):R45
   PubMed Web of Science ®Google Scholar
• Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 2008;8(2):87-93
   PubMedGoogle Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54(3):692-701
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56(9):2886-95
   PubMed Web of Science ®Google Scholar
• Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60(11):3180-9
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12(1):R5
   PubMed Web of Science ®Google Scholar
• Carmona L, Abasolo L, Descalzo MA, et al.; BIOBADASER Study Group; EMECAR Study Group. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011;41(1):71-80
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69(2):400-8
   PubMed Web of Science ®Google Scholar
• Hellgren K, Smedby KE, Feltelius N, et al. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 2010;62(5):1252-8
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
   PubMed Web of Science ®Google Scholar
• Bender NK, Heilig CE, Dröll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-15
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al.; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62(1):22-32
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Reed G, Decktor D, et al.; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71(7):1134-42
   PubMed Web of Science ®Google Scholar
• Bazzani C, Filippini M, Caporali R, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 2009;8(3):260-5
   PubMed Web of Science ®Google Scholar
• Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 2009;1173:837-46
   PubMed Web of Science ®Google Scholar
• Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67(9):1229-34
   PubMed Web of Science ®Google Scholar
• Iannone F, Gremese E, Atzeni F, et al. Gruppo Italiano di Studio sulle Early Arthritides (GISEA). Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012;39(6):1179-84
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59(2):234-40
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii13-16
   PubMed Web of Science ®Google Scholar
• Lee YH, Woo JH, Rho YH, et al. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008;28(6):553-9
   PubMed Web of Science ®Google Scholar
• Brocq O, Roux CH, Albert C, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74(2):148-54
   PubMed Web of Science ®Google Scholar
• Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33(12):2433-8
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65(1):28-38
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Weinblatt ME, Schiff M, et al. 2-year results from the ample (abatacept versus adalimumab comparison in biologic-naïve RA patients with background methotrexate) trial: changes in patient-reported outcomes in response to subcutaneous abatacept or adaliumab in rheumatoid arthritis. Arthritis Rheum 2013;65(Suppl):S183
   Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al.; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381(9877):1541-50
   PubMed Web of Science ®Google Scholar
• Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009;68(6):930-7
   PubMed Web of Science ®Google Scholar
• Bejarano V, Quinn M, Conaghan PG, et al.; Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59(10):1467-74
   PubMed Web of Science ®Google Scholar
• Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22(6):814-22
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Harigai M, Takeuchi T, et al.; GO-FORTH Study Group. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012;71(6):817-24
   PubMed Web of Science ®Google Scholar